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Abstract
The transcription factor AP-2a functions as a tumor suppressor by regulating various genes that are involved in cell
proliferation and apoptosis. Chemotherapeutic drugs including cisplatin induce post-transcriptionally endogenous AP-2a,
which contributes to chemosensitivity by enhancing therapy-induced apoptosis. microRNAs (miRNAs) miR-200b, miR-200c
and miR-429 (miR-200b/200c/429) are up-regulated in endometrial and esophageal cancers, and their overexpression
correlates with resistance to cisplatin treatment. Using computational programs, we predicted that the 39 untranslated
region (UTR) of AP-2a gene contains a potential miRNA response element (MRE) for the miR-200b/200c/429 family, and the
single nucleotide polymorphism (SNP) site rs1045385 (A or C allele) resided within the predicted MRE. Luciferase assays and
Western blot analysis demonstrated that the miR-200b/200c/429 family recognized the MRE in the 39 UTR of AP-2a gene
and negatively regulated the expression of endogenous AP-2a proteins. SNP rs1045385 A.C variation enhanced AP-2a
expression by disrupting the binding of the miR-200b/200c/429 family to the 39 UTR of AP-2a. The effects of the two
polymorphic variants on cisplatin sensitivity were determined by clonogenic assay. The overexpression of AP-2a with
mutant 39 UTR (C allele) in the endometrial cancer cell line HEC-1A, which has high levels of endogenous miR-200b/200c/
429 and low levels of AP-2a protein, significantly increased cisplatin sensitivity, but overexpression of A allele of AP-2a has
no significant effects, compared with mock transfection. We concluded that miR-200b/200c/429 induced cisplatin resistance
by repressing AP-2a expression in endometrial cancer cells. The SNP (rs1045385) A.C variation decreased the binding of
miR-200b/200c/429 to the 39 UTR of AP-2a, which upregulated AP-2a protein expression and increased cisplatin sensitivity.
Our results suggest that SNP (rs1045385) may be a potential prognostic marker for cisplatin treatment.
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Introduction
The AP-2 family of transcription factors is involved in the
regulation of embryonic development, cell proliferation and
tumorigenesis. To date, five members of the AP-2 family have
been identified: AP-2a, AP-2b, AP-2c, AP-2d and AP-2e. All AP-2
proteins bind as homo- or heterodimers to the consensus sequence
of 59- GCCNNNGGC-39 and directly regulate transcription of
their target genes (reviewed in [1]). Among these, AP-2a is the
best-characterized gene. The importance of AP-2a during
embryogenesis has been demonstrated using knock-out mice
studies. Loss of AP-2a leads to defects in the neural tube, face,
eyes, heart, body wall and limbs [2,3,4]. In addition to its roles in
embryonic development, AP-2a functions as a tumor suppressor
by regulating the transcription of various genes that are involved in
cell proliferation and apoptosis. AP-2a regulates the transcription-
al activation of p21WAF1/CIP1[5], E-cadherin[6] and PTEN[7]
and transcriptional repression of Bcl-2[8], vascular endothelial
growth factor[9] and mucin MUC4 [10]. AP-2a expression is
down-regulated in skin, brain, breast, ovarian and colon cancers,
and its lower expression predicts poor survival of pa-
tients[11,12,13]. Moreover, several studies have shown that AP-
2a status is associated with the chemosensitivity of cancer
cells[14,15,16]. Endogenous AP-2a protein is posttranscriptionally
induced by various chemotherapeutic drugs, including cisplatin,
adriamycin and taxol, and promotes chemosensitivity by enhanc-
ing therapy-induced apoptosis in colon and breast cancer cells
[14]. A moderate overexpression of AP-2a in pancreatic cancer
cell line CAPAN-1 increased the chemosensitivity to low doses of
gemcitabine[15]. The expression of AP-2a in the lung carcinoma
cell line H460 increased the chemosensitivity to adriamycin (2.5-
fold) and cisplatin (5-fold)[16].
Recently, microRNAs (miRNAs) have attracted more attention
because they have regulatory roles in a broad range of biological
processes, including embryogenesis, differentiation, proliferation
and apoptosis, as well as in carcinogenesis. The miRNAs are a
class of small (approximately 22 nucleotides), single-stranded,
endogenous non-coding RNAs that negatively regulate gene
expression by binding to the 39 untranslated region (UTR) of
target mRNA to inhibit translation and/or promote mRNA
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genes are regulated by miRNAs[19]. Therefore, we proposed that
miRNA might also regulate AP-2a. Using several computational
programs, we identified a potential binding site (miRNA response
element, MRE) of miR-200b, miR-200c and miR-429 (miR-
200b/200c/429) in the 39 UTR of the AP-2a gene. The miRNAs
miR-200b/200c/429 share a common seed sequence of AAUA-
CUG[20] and are highly expressed in endometrial cancers than in
normal endometrial tissues[21]. In this report, we demonstrated
that AP-2a was directly regulated by miR-200b/200c/429 family
and that the single nucleotide polymorphism (SNP) rs1045385 was
located in the miR-200b/200c/429-binding site of the 39 UTR of
AP-2a and affected AP-2a protein expression and cisplatin
resistance in endometrial cancer cells.
Results
The 39 UTR of AP-2a gene contains a MRE for miR-200b/
200c/429 family
To identify the miRNAs that regulated AP-2a, we used four
computational programs (TargetScan, Microcosm, DIANA-mi-
croT and miRanda) to search for MREs in the 39-UTR of the AP-
2a gene. Each program predicted different MREs. However, the
programs identified a common MRE for the miR-200b/200c/429
family (Fig. 1a). Moreover, this putative MRE was highly
conserved in vertebrates (data not shown).
We validated whether the predicted MRE could be recognized
by the miR-200b/200c/miR-429 family using the dual-luciferase
vector pmirGLO. The predicted MRE, wild-type or MRE-deleted
39 UTR of AP-2a was cloned downstream of the firefly luciferase
of the pmirGLO vector and co-transfected with miR-200b, miR-
200c or miR-429 mimics (double-stranded processed miRNA) into
HEK293 cells, which do not express miR-200b, miR-200c or
miR-429[21]. As shown in Fig.1b, the expression of miR-200b,
miR-200c or miR-429 suppressed the firefly luciferase activities of
MRE and the MRE-containing 39 UTR of AP-2a. However, the
luciferase activity was restored using MRE-deleted 39 UTR of AP-
2a. These results indicate that the predicted MRE mediates the
binding of the miR-200b/200c/429 family to AP-2a.
The miR-200b/200c/429 family represses endogenous
AP-2a expression
To examine the effect of the miR-200b/200c/429 family on
endogenous AP-2a expression, we transfected miR-200b, miR-
200c or miR-429 mimics into cervical cancer HeLa cells, which is
known to express high levels of AP-2a protein[22]. Enhanced
expression of miR-200b, miR-200c or miR-429 in HeLa cells
significantly decreased the amount of AP-2a protein, compared
with mock transfection (Fig. 2a).
To further confirm these results, we blocked the expression of
miR-200b, miR-200c or miR-429 using miRNA inhibitors (single-
stranded complementary miRNA) in the endometrial cancer cell
line HEC-1A, which has been shown to express higher levels of
miR-200b, miR-200c or miR-429[21]. Cells that were untreated
or transfected with a negative control expressed low levels of AP-
2a. However, the silencing of miR-200b, miR-200c and miR-429
significantly increased AP-2a levels, compared with mock
transfection (Fig. 2b).
These results demonstrate that miR-200b, 200c and miR-429
negatively regulate AP-2a expression.
SNP rs1045385 A.C variation enhances AP-2a
expression by interfering with the miR-200b/200c/429
family
By searching the Ensembl database, we identified a SNP
(rs1045385) in the miR-200b/200c/429-binding MRE of the AP-
2a 39 UTR. The SNP rs1045385 has two alleles, A and C alleles
(Fig. 3a). To investigate the effect of SNP rs1045385 A.C
variation on miRNA binding, the wild-type and mutant 39 UTR
were cloned into the dual-luciferase reporter vector pmirGLO and
co-transfected with miRNA mimics into HEK293 cells. As shown
Figure 1. The 39 UTR of AP-2a contains a MRE for miR-200b/200c/429 family. A) Diagram of luciferase reporter constructs. The predicted
MRE, wild-type or MRE-deleted AP-2a 39 UTRs were inserted downstream of the firefly luciferase gene of the pmirGLO vector. B) Repression of firefly
luciferase by the interaction between miRNA and the predicted MRE. Each luciferase construct was co-transfected with miR-200b, miR-200c or miR-
429 mimics into HEK293 cells. At 24 h post-transfection, the luciferase activity was examined. The firefly luciferase activity was normalized to Renilla
luciferase activity. The firefly luciferase activity of the cells that were transfected with miRNA mimics was represented as the percent activity relative
to that of the cells that were transfected with negative control miRNA mimics. Data are shown as the mean6SD of three independent experiments.
**, p,0.01.
doi:10.1371/journal.pone.0029043.g001
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activity of the AP-2a 39 UTR, indicating A.C substitution
suppressed the binding of miR-200b/200c/miR-429 to their
target.
To determine the effect of SNP rs1045385 on miR-200b/200c/
miR-429-mediated regulation of AP-2a, we generated expression
constructs of AP-2a containing a wild-type 39 UTR or a mutant 39
UTR, i.e., pMyc-AP-2a (A) and pMyc-AP-2a (C), respectively,
and co-transfected them with miR-200b, miR-200c or miR-429
mimics into HEK293 cells. The overexpression of miR-200b or
miR-200c decreased the expression of the AP-2a gene with a wild-
type 39 UTR but had no effect on that of the AP-2a gene with a
mutant 39 UTR (Fig. 3c). Although miR-429 transfection
suppressed the expression of wild-type and mutant AP-2a, the
cells transfected with the mutant AP-2a gene had higher AP-2a
protein levels than those transfected with the wild-type AP-2a
gene. The expression of wild-type and MRE-mutated AP-2a was
suppressed by miR-429, suggesting that the 39 UTR of AP-2a
contained another binding site for miR-429.
Taken together, these results indicate that SNP rs1045385 A.C
variation mediates AP-2a upregulation by disrupting the binding
of miR-200b/200c/429 to the 39 UTR of AP-2a.
SNP rs1045385 A.C variation increases cisplatin
sensitivity of HEC-1A cells
As stated above, SNP rs1045385 A.C variation enhanced the
expression of AP-2a protein, while AP-2a overexpression has been
shown to promote chemosensitivity in tumor cells[14,15,16].
Therefore, we tested whether SNP rs1045385 affected the
response to cisplatin treatment. HEC-1A cells were transfected
with wild-type (A allele) or MRE-mutated (C allele) AP-2a cDNA
constructs, and treated with various concentrations of cisplatin for
6 h. The result of the clonogenic assay showed that the
transfection of C allele of AP-2a significantly inhibited cell
viability, but overexpression of A allele of AP-2a has no significant
effects, compared with mock transfection. At concentrations
higher than 10 mM, the survival fraction of the cells that were
transfected with mutant AP-2a was significantly lower than that of
the cells that were transfected with wild-type AP-2a (Fig. 4). As
stated above, the mutant AP-2a was insensitive to miR-200b/
Figure 2. The miR-200b/200c/429 family represses endogenous
AP-2a expression. The miRNA mimics and inhibitors were transfected
into HeLa cells (A) and HEC-1A cells (B), respectively. At 36 h after
transfection, cells lysates were prepared and subjected to Western blot
analysis.
doi:10.1371/journal.pone.0029043.g002
Figure 3. SNP rs1045385 A.C variation in the AP-2a 39 UTR inhibits the binding of the miR-200b/200c/429 family and enhances AP-
2a expression. A) Diagram of the binding between miR-200b/200c/429 seed sequence and the AP-2a 39 UTR with the A or C allele. B) SNP
rs1045385 A.C variation in the AP-2a 39 UTR inhibited the binding of the miR-200b/200c/429 family. HEK293 cells were transfected with indicated
miRNA mimics and luciferase reporter constructs containing the AP-2a 39 UTR with the A or C allele. At 24 h post-transfection, luciferase activity was
examined. The firefly luciferase activity was normalized to the Renilla luciferase activity. The firefly luciferase activity of the cells that were transfected
with miRNA mimics was represented as the percent activity relative to that of the cells that were transfected with negative control miRNA mimics.
**, p,0.01. C) SNP rs1045385 A.C variation in the AP-2a 39 UTR enhanced the AP-2a expression in HEC-1A cells. The Myc-tagged expression
construct of full-length AP-2a with the A or C allele was co-transfected with miRNA mimics into HEC-1A cells. At 36 h after transfection, cell lysates
were prepared and subjected to Western blot analysis.
doi:10.1371/journal.pone.0029043.g003
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levels of AP-2a protein in the HEC-1A cells containing higher
levels of miR-200b/200c/429 than those with wild-type AP-2a,
which exhibited increased cisplatin sensitivity. These results
indicate that SNP rs1045385 A.C variation increases cisplatin
sensitivity in HEC-1A cells.
Discussion
Here, we present evidence that miR-200b, miR-200c and miR-
429 are negative regulators of AP-2a. Using computational
programs, we predicted that the 39 UTR of AP-2a contained a
potential binding site for miR-200b, miR-200c and miR-429. We
validated the binding of miR-200b/200c/429 to the 39 UTR of
AP-2a using the luciferase assay. Finally, we examined the effects
of miR-200b, miR-200c and miR-429 on the expression of
endogenous AP-2a. Ectopic expression of miR-200b, miR-200c or
miR-429 suppressed the expression of AP-2a in HeLa cells,
whereas inhibition of miR-200b, miR-200c or miR-429 in HEC-
1A enhanced the expression of AP-2a. To our knowledge, this is
the first report that has identified miRNAs that directly regulate
AP-2a.
Enhanced expression of AP-2a in cancer cells increase the
sensitivity to cisplatin[14,16]. The miR-200 family is highly
expressed in endometrial cancers than in normal endometrial
tissues, and its overexpression is correlated with cisplatin resistance
[21,23]. Lee et al. have reported that specific inhibition using anti-
miR-429 enhanced cisplatin-induced cytoxicity in HEC-1 cells. In
this study, we showed that AP-2a overexpression in endometrial
cancer HEC-1 cells also increased the sensitivity to cisplatin
treatment. The cells that were transfected with mutant AP-2a,
which contains a mutated 39 UTR that cannot bind to miR-200b/
200b/429, were more sensitive to cisplatin than the cells with wild-
type AP-2a. These results suggest that miR-200b/miR-200c/miR-
429 overexpression induces cisplatin resistance by repressing AP-
2a expression in HEC-1 cells.
SNPs are the most common type of genetic variation in human
genomes. When SNPs are located at or near a MRE of a
functional gene, they may affect gene expression by altering the
interaction between miRNA and mRNA [24,25]. Increasing
evidence has suggested that MRE polymorphisms are associated
with tumor susceptibility and chemotherapeutic re-
sponse[24,26,27]. For example, a miR-4-binding site polymor-
phism in the dihydrofolate reductase gene leads to methotrexate
resistance[26]. Therefore, identifying SNPs that are associated
with cancer and chemosensitivity is valuable for personalized
cancer diagnostic and therapeutic approaches. Several studies
have shown that AP-2a status is associated with the chemosen-
sitivity of cancer cells[14,15,16] Here, we found that the SNP
(rs1045385) A.C variation in the AP-2a 39 UTR disrupted the
interaction between the miR-200b/200c/429 family and AP-2a,
which upregulated AP-2a expression and AP-2a-mediated cis-
platin sensitivity. Our results suggest that SNP rs1045385 may be a
potential prognostic marker for cisplatin treatment and that
patients with the C allele of SNP rs1045385 may be more sensitive
to chemotherapy than those with the wild-type A allele of SNP
rs1045385.
Materials and Methods
Computational analysis of MRE
The 39 UTR of the AP-2a gene was obtained from the Ensembl
database (http://www.ensembl.org). The following computational
programs were used to search for potential MREs in the 39 UTR
of the AP-2a gene: TargetScan[19] (http://www.targetscan.org/),
MicroCosm Targets (http://www.ebi.ac.uk/enright-srv/microcosm),
DIANA-microT[28] (http://diana.cslab.ece.ntua.gr/microT) and
miRanda[29] (http://www.microrna.org).
Construction and mutagenesis of dual-luciferase reporter
plasmids and AP-2a expression plasmids
The 39 UTR of AP-2a was amplified from HeLa cDNA using a
nested PCR and was inserted into the 39-end of the firefly
luciferase gene of the dual-luciferase miRNA target expression
vector pmirGLO (Promega Corporation, Madison, WI, USA)
between Pmel and XbaI sites. The oligonucleotide pairs that
contain the MRE of the desired miRNA were designed to form
overhangs that were complementary to those generated by the
annealed fragments of PmeI and XbaI digestion. The oligonucle-
otide pairs were synthesized, annealed and ligated into the
pmirGLO vector. The full AP-2a cDNA construct containing
the entire 39 UTR was constructed by inserting the 39 UTR of AP-
2a into a Myc-tagged AP-2a expression plasmid. Deletion and
site-directed mutagenesis were performed by overlapping PCR as
described previously[30].
Cell culture and transfection
Human embryonic kidney-293 (HEK293) cells, cervical cancer
HeLa cells and endometrial cancer HEC-1A cells (from American
Tissue Culture Collection, ATCC, Manassas, VA,USA) were
cultured in DMEM or McCoy’s 5a media that was su\lemented
with glutamine, antibiotics and 10% fetal bovine serum at 37uC
and 5% CO2. Transfection was performed using Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s instructions.
Luciferase assay
The dual-luciferase reporter plasmids were co-transfected with
miRNA mimics (GenePharma, Shanghai, China) into HEK293
cells. At 24 h post-transfection, cells were assayed for luciferase
activity using the Dual-Glo Luciferase Assay System (Promega)
according to the manufacturer’s instructions. The firefly luciferase
activities were normalized to Renilla luciferase activity. The firefly
luciferase activity of the cells that were transfected with miRNA
Figure 4. SNP rs1045385 A.C variation increases cisplatin
sensitivity of HEC-1A cells. The Myc-tagged expression constructs of
full-length AP-2a with the A or C allele were transfected into HEC-1A
cells. At 12 h after transfection, the cells were plated in 6-well plates,
and treated with the indicated concentration of cisplatin for 6 h. The
cell viability was determined using the clonogenic assay. Data are
shown as the mean6SD of three independent experiments. **, p,0.01.
doi:10.1371/journal.pone.0029043.g004
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the cells that were transfected with negative control miRNA
mimics. For each transfection, the luciferase activity was averaged
from three replicates.
Western blot analysis to assess the effects of miRNA
mimics and inhibitors on AP-2a expression
All of the miRNA mimics and inhibitors that were used in this
study were purchased from GenePharma (Shanghai, China). At
36 h posttransfection, cells were harvested and lysed in RIPA
buffer [50 mM Tris–HCl (pH 7.2), 150 mM NaCl, 1% (v/v)
Triton X-100, 1% (w/v) sodium deoxycholate, 0.1% (w/v) SDS]
with protease inhibitors. Proteins were separated on 10% SDS-
polyacrylamide gel and transferred to PVDF membranes. A
PageRuler prestained protein ladder was used as a molecular
marker. A single membrane was cut into two parts at the 40-kD
band and incubated with anti-AP-2a (Abcam, Cambridge, UK)
and anti-GAPDH (Santa Cruz, CA, USA) primary antibodies,
respectively. The protein was detected using a HRP-conjugated
secondary antibody and a ChemiLucent ECL Detection System
(Millipore, Billerica, MA, USA).
Cisplatin treatment and clonogenic assays
The clonogenic assay was performed as described by Franken et
al[31]. HEC-1 cells were transfected with expression constructs of
AP-2a containing a wild-type or mutant 39 UTR. At 12 h
posttransfection, the cells were plated in 6-well plates, and treated
with various concentrations (0, 5, 10,15,20,25 mmol/L) of cisplatin
(Sigma-Aldrich) for 6 h. After treatment, cells were maintained in
fresh media for 2 weeks. Colonies were fixed with methanol and
stained with Giemsas for 20 min. The cell viability was analyzed
by the surviving fraction[31].
Statistical analysis
Microsoft Excel was used for statistical analysis. Student’s t-test
was performed to evaluate the significance of difference between
samples.
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